Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD - Nasdaq - US21900C3088 - Common Stock - Currency: USD

12.56  -0.05 (-0.4%)

Fundamental Rating

7

CRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CRMD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CRMD is evaluated to be cheap and growing strongly. This does not happen too often! This makes CRMD very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year CRMD was profitable.
CRMD had a negative operating cash flow in the past year.
CRMD had negative earnings in each of the past 5 years.
In the past 5 years CRMD always reported negative operating cash flow.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of CRMD (11.49%) is better than 93.78% of its industry peers.
CRMD's Return On Equity of 14.95% is amongst the best of the industry. CRMD outperforms 89.64% of its industry peers.
CRMD has a better Return On Invested Capital (9.93%) than 87.56% of its industry peers.
Industry RankSector Rank
ROA 11.49%
ROE 14.95%
ROIC 9.93%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

CRMD has a better Profit Margin (20.81%) than 94.30% of its industry peers.
The Operating Margin of CRMD (17.53%) is better than 86.53% of its industry peers.
Looking at the Gross Margin, with a value of 95.19%, CRMD belongs to the top of the industry, outperforming 97.41% of the companies in the same industry.
CRMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 17.53%
PM (TTM) 20.81%
GM 95.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRMD is destroying value.
The number of shares outstanding for CRMD has been increased compared to 1 year ago.
Compared to 5 years ago, CRMD has more shares outstanding
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 14.98 indicates that CRMD is not in any danger for bankruptcy at the moment.
The Altman-Z score of CRMD (14.98) is better than 90.67% of its industry peers.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.98
ROIC/WACC0.99
WACC10.01%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

CRMD has a Current Ratio of 4.21. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.21, CRMD is doing good in the industry, outperforming 64.77% of the companies in the same industry.
CRMD has a Quick Ratio of 3.99. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.99, CRMD is in the better half of the industry, outperforming 64.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 3.99
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

CRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 180.65%, which is quite impressive.
CRMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 174.29% yearly.
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%

3.2 Future

Based on estimates for the next years, CRMD will show a very strong growth in Earnings Per Share. The EPS will grow by 53.20% on average per year.
The Revenue is expected to grow by 51.29% on average over the next years. This is a very strong growth
EPS Next Y411.74%
EPS Next 2Y168.73%
EPS Next 3Y99.25%
EPS Next 5Y53.2%
Revenue Next Year308.3%
Revenue Next 2Y144.03%
Revenue Next 3Y91.01%
Revenue Next 5Y51.29%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 16.75, which indicates a correct valuation of CRMD.
Based on the Price/Earnings ratio, CRMD is valued cheaply inside the industry as 84.97% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.93, CRMD is valued a bit cheaper.
A Price/Forward Earnings ratio of 7.29 indicates a rather cheap valuation of CRMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 90.67% of the companies listed in the same industry.
CRMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.31, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.75
Fwd PE 7.29
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

CRMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CRMD is cheaper than 76.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 56.86
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of CRMD may justify a higher PE ratio.
A more expensive valuation may be justified as CRMD's earnings are expected to grow with 99.25% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y168.73%
EPS Next 3Y99.25%

More info and screens

0

5. Dividend

5.1 Amount

CRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (8/15/2025, 1:31:11 PM)

12.56

-0.05 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners34.07%
Inst Owner Change3.12%
Ins Owners1.08%
Ins Owner Change1.62%
Market Cap933.46M
Analysts81.54
Price Target20.06 (59.71%)
Short Float %13.67%
Short Ratio5.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.59%
Min EPS beat(2)13.12%
Max EPS beat(2)54.06%
EPS beat(4)4
Avg EPS beat(4)30.36%
Min EPS beat(4)1.96%
Max EPS beat(4)54.06%
EPS beat(8)6
Avg EPS beat(8)15.62%
EPS beat(12)8
Avg EPS beat(12)11.61%
EPS beat(16)11
Avg EPS beat(16)11.55%
Revenue beat(2)2
Avg Revenue beat(2)9.51%
Min Revenue beat(2)3.69%
Max Revenue beat(2)15.32%
Revenue beat(4)3
Avg Revenue beat(4)-7.54%
Min Revenue beat(4)-52.8%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.92%
PT rev (3m)26.88%
EPS NQ rev (1m)8.04%
EPS NQ rev (3m)73.73%
EPS NY rev (1m)0%
EPS NY rev (3m)48.1%
Revenue NQ rev (1m)2.95%
Revenue NQ rev (3m)25.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.18%
Valuation
Industry RankSector Rank
PE 16.75
Fwd PE 7.29
P/S 11.31
P/FCF N/A
P/OCF N/A
P/B 8.12
P/tB 8.25
EV/EBITDA 56.86
EPS(TTM)0.75
EY5.97%
EPS(NY)1.72
Fwd EY13.72%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS1.11
BVpS1.55
TBVpS1.52
PEG (NY)0.04
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.49%
ROE 14.95%
ROCE 12.56%
ROIC 9.93%
ROICexc 30.34%
ROICexgc 31.85%
OM 17.53%
PM (TTM) 20.81%
GM 95.19%
FCFM N/A
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 14.36%
Cap/Sales 0.08%
Interest Coverage 395.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.21
Quick Ratio 3.99
Altman-Z 14.98
F-Score5
WACC10.01%
ROIC/WACC0.99
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
EPS Next Y411.74%
EPS Next 2Y168.73%
EPS Next 3Y99.25%
EPS Next 5Y53.2%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%
Revenue Next Year308.3%
Revenue Next 2Y144.03%
Revenue Next 3Y91.01%
Revenue Next 5Y51.29%
EBIT growth 1Y126.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year489.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.56%
OCF growth 3YN/A
OCF growth 5YN/A